Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T13:31:01.718Z.
Calculation as of: 2026-10-06T13:31:01.718Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f12fe6f09ebba39ad61e3a87243b01e46bba3d7bd48a90cbad4cda1dbeff8bd9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$49.40M
Free Cash Flow Yield
39.84%
TTM Avg
42.72%
3Y Avg
26.54%
5Y Avg
31.80%
Market Cap
$52.80M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.71M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clene Inc. (CLNN) | $49.84M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.72M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $49.21M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $51.17M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $49.40M | 39.84% | 42.72% | 26.54% | 31.80% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.80M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.84M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.71M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
